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New atypical antipsychotics have opened a new era in the
treatment of schizophrenia owing to their effectiveness
both on positive, but especially negative, symptoms,
without extrapyramidal side-effects (Tandon et al., 1999).
The archetypal atypical antipsychotic is clozapine, whose
main side-effect is agranulocytosis. Recently, other new
atypical antipsychotics have been developed, such as
olanzapine (Stephenson and Pilowsky, 1999), which do
not produce any adverse haematological effects (Beasley
et al., 1997). Clozapine and olanzapine share lower D2
and D3 receptor affinity in the basal ganglia and nigro-
striatal system, and higher affinity to muscarinic (M) and
histaminergic (H) receptors than haloperidol. Moreover,
clozapine has higher affinity to adrenergic (a1 and a2)
receptors, while olanzapine has higher affinity to D2, D3,
D4 and serotonergic (5-HT-2A) receptors (ratio 5-HT-
2A}D2" 2) (Coward, 1992). The pharmacological
profile can explain the efficacy of these drugs not only on
the positive, but also especially on the negative
symptoms, representing the originality of new anti-
psychotic treatment. The improvement of primary nega-
tive symptoms (Crow, 1980) and the absence of secondary
symptoms (produced by extrapyramidal side-effects)
result in an increased compliance (Marder, 1998) and
improvement of cognitive functions (insight capacity,
self-awareness, judgement) (Meyer-Lindenberg et al.,
1997).
The aim of our study was to evaluate the effectiveness
of clozapine and olanzapine in the treatment of schizo-
phrenic patients in our psychiatric department. This is
constituted by hospital wards connected to community
services (outpatient care, semi-residential and residential
centres for rehabilitative social programmes).
Subjects and clinical assessments
All patients admitted to our psychiatric wards (Presidio
Psichiatrico di Diagnosi e Cura 1) with schizophrenia
diagnosis and schizoid personality disorders (according to
DSM-IV) (American Psychiatric Association, 1994), and
treated with clozapine and olanzapine from September
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1995 to September 1998 were selected. Previously these
patients had never been treated with these drugs, only
with traditional neuroleptics. The sample consisted of 25
patients : 12 treated with clozapine and 13 with
olanzapine. In the clozapine group 10 patients were
affected by paranoid and 2 by disorganized schizophrenia ;
in the olanzapine group 4 patients were affected by
paranoid, 3 by disorganized, 3 by catatonic, 1 by
undifferentiated schizophrenia and 2 by schizoid per-
sonality disorder, according to DSM-IV criteria. The
sample size was conditioned by the difficulty in selecting
patients whose clinical features were similar enough to be
compared.
The atypical neuroleptic treatments were evaluated for
a whole period of 482–08‡29–42 d for the clozapine
group and 207–30‡30–26 d for the olanzapine group
(patients treated for a period less than 30 d were excluded
from our study) composed of a period of in-patient care
(overlapped for the two groups : 43–3‡4–49 d for
clozapine, 44–23‡4–45 d for olanzapine) and the fol-
lowing outpatient care. The therapeutic dose ranges were :
from 250 to 600 mg}d for clozapine and from 10 to
30 mg}d for olanzapine. Clozapine (Leponex, Novartis
Farma SpA, Origgio Varese, Italy) and olanzapine
(Ziprexa, Eli Lilly, Nieuwegein, The Netherlands) were
used. The procedures followed were in accordance
with the ethical standards of the Institutional Ethical
Committee on human experimentation.
The following clinical features of the sample were
analysed : age, diagnosis, previous illness duration, rate of
hospitalization and previous neuroleptical treatment
(effectiveness, compliance, tolerance and side-effects).
Clinical symptoms were assessed by means of Brief
Psychiatric Rating Scale (BPRS) (Overall and Gorham,
1962) at admission and discharge. Social functioning was
evaluated by means of the Global Assessment of
Functioning (GAF) scale (Spitzer et al., 1979) at admission
and at the end of the follow-up period. The rate of the
rehospitalization under atypical neuroleptics treatment
was evaluated. Moreover, patients’ compliance with
rehabilitative outdoor programmes under clozapine and
olanzapine treatment was assessed at the end of follow-up
period. Data were analysed by means of ANOVA, Fisher
test and Kruskal–Wallis test, and expressed as mean‡s.e.
(Statistica, Version 5, ’97 Edition, Statsoft, Italy).
The two groups were significantly different for mean
age (40–75‡6–27 yr in clozapine-treated patients,
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Table 1. Influence of clozapine and olanzapine treatments on BPRS score
BPRS score items
Clozapine Olanzapine
Admission Discharge Admission Discharge
Unusual thought content 6–54 4–91* 6–07 4–07*
Suspiciousness 6–00 3–36* 5–54 2–76*
Conceptual disorganization 5–00 2–64* 4–69 2–61*
Distractibility 5–00 2–36* 3–00 1–46*
Bizarre behaviour 5–91 3–91* 6–46 3–23*
Self-neglect 4–82 2–18* 5–31 2–46*
Hostility 5–54 2–55* 5–93 2–46*
Tension 6–18 2–82* 5–38 3–00*
Anxiety 5–55 3–00* 4–23 2–31
Hallucinations 6–27 4–36* 4–38 3–00
Mannerism and posturing 5–00 3–64 5–15 3–00*
Emotional withdrawal 3–73 2–27 5–38 2–38*
Blunted affect 3–91 2–45 5–15 3–00*
* p! 0–05 (at least) vs. admission of clozapine and olanzapine group respectively.
 p! 0–009 vs. discharge of clozapine group. Kruskal–Wallis test.
33–15‡8–45 yr in olanzapine-treated patients) and pre-
vious illness duration (18–58‡8–16 yr in the clozapine
group, 9–92‡8–78 yr in the olanzapine group), but
both groups presented the same rate of previous
hospitalization, quantified in number of admission}illness
days (4–41‡4–38 d in the clozapine group, 3–43‡2–92 d
in the olanzapine group) and similar compliance, effective-
ness and side-effects with previous neuroleptical treat-
ments (7 patients in the clozapine group and 9 in the
olanzapine group had rarely and irregularly taken the
previous therapy ; 8 patients under clozapine therapy and
6 under olanzapine therapy did not present any sympto-
matic improvement, while all others presented only a
mild improvement ; 9 patients in each group were not
affected by important side-effects). Further, at admission,
the score of BPRS items was similar for the two groups as
well as the GAF scale score.
Our results have shown that at discharge, both
clozapine and olanzapine treatments significantly de-
creased the BPRS score of the following items (Table 1) :
unusual thought content, suspiciousness, conceptual
disorganization, distractibility, bizarre behaviour, self-
neglect, hostility, tension.
The score of anxiety and hallucinations was sig-
nificantly decreased by clozapine therapy, while man-
nerism and posturing, emotional withdrawal, blunted
affect score were significantly ameliorated by olanzapine
therapy (Table 1). Only the score of distractibilty was
significantly reduced by olanzapine in comparison with
the clozapine group (Table 1).
Both drugs significantly reduced the rate of
hospitalization during the treatment evaluated as percent
of admissions before and under treatment (from 100 to
25% in clozapine group ; from 100 to 23% in the
olanzapine group, pfl 0–0002 and pfl 0–0001, respect-
ively, Fisher test). At the end of the follow-up period, the
GAF score of both groups was significantly increased
(from 26–66‡2–84 to 37–08‡1–89 in the clozapine
group ; from 25–00‡3–15 to 46–53‡4–09 in olanzapine
group, at least p! 0–005 ANOVA) but the GAF score
of the olanzapine group was significantly higher than
that of the clozapine group, in spite of a shorter period
of treatment (p! 0–05, ANOVA). Moreover, both
atypical neuroleptics facilitated the patients’ participation
in psychosocial rehabilitative programs : 7 olanzapine-
treated patients began a semi-residential centre activity
and 2 patients again started competitive work ; 2
clozapine-treated patients were admitted to residential
centres and 2 patients began a social training programme.
Discussion
Our sample was constituted by ‘non-responsive ’ patients,
who were affected by a severe psychotic disturbance, as
demonstrated by long period of illness, high rate of
hospitalization and low GAF score at admission. Either
clozapine or olanzapine significantly ameliorated positive
symptoms, but only clozapine was effective in reducing
anxiety and hallucinations, while olanzapine was more
effective in reducing negative symptoms, such as man-
nerism and posturing, blunted affect and emotional
withdrawal. Olanzapine-treated patients obtained signifi-
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cantly higher GAF scores than clozapine-treated patients
and more frequently participated in rehabilitative pro-
grammes (9 olanzapine-treated patients vs. 4 clozapine-
treated patients). This result could be due to the difference
of age and previous illness period between the two
groups : clozapine-treated patients were 7.5 yr older and
fell ill 9 yr earlier than olanzapine-treated patients. But the
two groups were not significantly different in other
clinical features (the rate of previous hospitalization, GAF
scale and score of BPRS items) which might have affected
the therapeutic efficacy. Finally, the clozapine treatment
period was longer than olanzapine treatment but, in any
case, we compared clozapine- to olanzapine-treated
patients, because we observed an early and dramatic
improvement of psychotic symptoms with olanzapine
treatment.
In conclusion, even though the two groups were small
and not completely comparable, the data suggest that the
improvement of negative and positive symptoms,
associated with a more tolerable side-effects profile,
enhances therapeutic compliance and permits regular
therapy that, consequently, prevents relapses. Moreover,
olanzapine therapy has surprisingly been shown to be
more effective than clozapine in improving social and
working skills.
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